Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
-
Publication number: 20100092455Abstract: The present invention relates to novel isolated antibodies, or the derived compounds or functional fragments of same, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo, said antibodies having been obtained by functional screening. More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies are also covered.Type: ApplicationFiled: May 22, 2008Publication date: April 15, 2010Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Nathalie Corvaia, Jean-Francois Haeuw, Cedric Bes
-
Publication number: 20100093039Abstract: Culture media for in vitro cell culture which contain substantially saturated amounts of selected amino acids improve protein production, constrain cell growth and extend cell longevity, methods for the production and use of such media, and systems fox the production of protein utilizing such media and methods.Type: ApplicationFiled: October 12, 2009Publication date: April 15, 2010Inventors: Steve Oh Kah Weng, Florence Chua nee Ho Kit Fong
-
Publication number: 20100092484Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to CD44, and that function to inhibit CD44. The invention also relates to heavy and light chain immunoglobulins derived from human CD44 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human CD44 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions or medicaments for treatment.Type: ApplicationFiled: December 20, 2007Publication date: April 15, 2010Inventors: Xu Xu, Vahe Bedian, Erika Meaddough, Haichun Huang, Lan Yang, Kristopher Toy, Mohan Srinivasan, Advait V. Badkar
-
Publication number: 20100092938Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.Type: ApplicationFiled: August 20, 2009Publication date: April 15, 2010Inventor: Samuel K. Martin
-
Patent number: 7695940Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.Type: GrantFiled: August 17, 2007Date of Patent: April 13, 2010Assignee: Biogen Idec MA Inc.Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
-
Publication number: 20100086997Abstract: Tyrosine receptor kinase (TrkB) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. TrkB agonists include naturally-occurring agonists, such as NT4 and BDNF, as well as agonists such as agonist antibodies.Type: ApplicationFiled: December 5, 2007Publication date: April 8, 2010Inventors: Chia-Yang Lin, Hua Long, David Liang Tsao
-
Publication number: 20100086522Abstract: The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic.Type: ApplicationFiled: July 18, 2007Publication date: April 8, 2010Applicant: OTTAWA HEALTH RESEARCH INSTITUTEInventors: John C. Bell, Anthony T. Power
-
Publication number: 20100062449Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.Type: ApplicationFiled: November 10, 2006Publication date: March 11, 2010Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
-
Publication number: 20100062462Abstract: This document relates to methods and materials involved in detecting, monitoring, and prognosing immunodeficiency virus infections. For example, methods and materials for determining whether or not a mammal (e.g., a human) has an immunodeficiency virus infection (e.g., an HIV infection), methods and materials for determining whether or not a mammal with an immunodeficiency virus infection is improving, and methods and materials for determining whether or not a mammal with an immunodeficiency virus infection has an advanced immunodeficiency virus infection are provided.Type: ApplicationFiled: December 14, 2006Publication date: March 11, 2010Inventors: Andrew D. Badley, Gary D. Bren, Zilin Nie
-
Publication number: 20100055675Abstract: Method for detecting a measles virus in an analyte, comprising forming a complex of a first monoclonal antibody being capable of binding to a first epitope of a measles virus nuclear protein and being immobilized on a solid phase, a second monoclonal antibody being capable of binding to a second epitope of a measles virus nuclear protein different from the first epitope and being labeled, and a measles virus nuclear protein contained in the analyte, on the solid phase; and detecting the measles virus based on the amount of the label of the complex formed on the solid phase, is disclosed. Membrane assay test device, and membrane assay test kit are also disclosed.Type: ApplicationFiled: August 28, 2009Publication date: March 4, 2010Applicant: SYSMEX CORPORATIONInventors: Hiroshi KUMAMOTO, Kouji Sakaguchi, Ayumi Asaeda, Takehiro Hasegawa, Naoya Okitsu, Noriaki Nakajima
-
Publication number: 20100056760Abstract: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents.Type: ApplicationFiled: May 29, 2009Publication date: March 4, 2010Applicant: SmithKline Beecham CorporationInventors: Julie A. ABRAHAMSON, Connie L. Erickson-Miller, Kristine K. Kikly, Bruce Bochner, Robert Schleimer, T. Esra Nutku
-
Publication number: 20100047166Abstract: Antibodies and molecules derived therefrom that bind to 58P1D12 protein and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.Type: ApplicationFiled: August 20, 2009Publication date: February 25, 2010Inventors: Steven B. KANNER, Aya Jakobovits, Jean Gudas, Arthur B. Raitano, Robert Kendall Morrison, Pia M. Challita-Eid, Xiao-chi Jia
-
Publication number: 20100047288Abstract: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.Type: ApplicationFiled: August 24, 2009Publication date: February 25, 2010Inventors: Thomas E. Wagner, Yanzhang Wei
-
Publication number: 20100047216Abstract: The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac disorders. Such late passage MSCs may be administered to the myocardium of a subject for induction of native cardiomyoctye proliferation and repair of cardiac tissue. Additionally, the late passage MSCs may be genetically engineered to express a gene encoding a physiologically active protein of interest and/or may be incorporated with small molecules for delivery to adjacent target cells through gap junctions. The late passage MSCs of the invention may be used to provide biological pacemaker activity and/or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and/or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker.Type: ApplicationFiled: July 20, 2007Publication date: February 25, 2010Inventors: Glenn Gaudette, Irina A. Potapova, Peter R. Brink, Ira S. Cohen, Richard B. Robinson, Michael R. Rosen
-
Publication number: 20100047257Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.Type: ApplicationFiled: July 13, 2007Publication date: February 25, 2010Applicant: SANOFI-AVENTISInventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
-
Publication number: 20100041743Abstract: The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins.Type: ApplicationFiled: November 23, 2007Publication date: February 18, 2010Inventors: Zsuzsanna Bösze, Imre Kacskovics, Judit Cervenak, László Hiripi, Balázs Bender
-
Patent number: 7662380Abstract: The antibody of the present invention has an extremely high binding ability to human ZAQL-1, can neutralize the activity of human ZAQL-1, and inhibits the action of human ZAQL-1. Therefore, the antibody is useful as a preventive or therapeutic agent or a diagnostic agent for, e.g., digestive diseases, diseases associated with angiogenesis, diseases relating to pregnancy, eating disorders, sleeping disorders, seasonal depression, reproductive dysfunction, endocrine diseases, senile dementia, Alzheimer's disease, various disorders caused by aging, cerebral circulatory disorders, head trauma, spinal injury, epilepsy, anxiety, depression, manic depression, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstral syndrome, glaucoma, cancer, AIDS, diabetes, etc.Type: GrantFiled: January 21, 2004Date of Patent: February 16, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Yasuko Horikoshi, Yasushi Masuda, Tetsuya Ohtaki
-
Publication number: 20100034866Abstract: Methods disclosed include methods of treating T1DM, said method comprising delivering a therapeutic amount of ?-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell.Type: ApplicationFiled: September 19, 2007Publication date: February 11, 2010Inventor: Christof Westenfelder
-
Publication number: 20100028946Abstract: Fusion partner cells that enable production of heterohybridomas even from cells of species other than mouse were produced by fusing myeloma cells derived from a first animal species with leukemia cells derived from a second animal species, which have an extra S phase in the cell cycle and have the property of diploidizing. Stable production of substances can be achieved by producing heterohybridomas through cell fusion between the fusion partner cells and substance-producing cells of an animal other than mouse.Type: ApplicationFiled: April 13, 2007Publication date: February 4, 2010Applicants: Medical & Biological Laboratories Co., Ltd.Inventors: Naomasa Yamamoto, Mizuho Kaneda
-
Publication number: 20100028901Abstract: The invention relates to the use of at least one of the following Formula (I) compounds: wherein n=1, Ra notably represents —COOH, Rb notably represents —CH3—, Z notably represents —CH2—CHOH—, wherein the compound may be in the form of salts or, if at least one asymmetric carbon atom is present, in the form of isolated isomers or as a racemic mixture, as a physiological marker for carrying out a method for the in vitro or ex vivo diagnosis of psychiatric disorders and/or intestinal dysbioses.Type: ApplicationFiled: April 13, 2007Publication date: February 4, 2010Applicant: AUREInventors: Celine Chery, Emmanuelle Lefebvre, Marc Merten
-
Patent number: 7651854Abstract: Disclosed herein are methods of increasing the proliferation of non-tumorigenic B cells. The methods involve administering PCDGF and optionally other B cells stimulators (e.g., IgM, LPS) to B cells resulting in an increase in B cell proliferation. The methods of the invention can be used, for example, to establish B cells lines, to sort B cells from a mixed population of cells, or to activate resting B cells.Type: GrantFiled: December 17, 2003Date of Patent: January 26, 2010Assignee: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20100015045Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: July 16, 2009Publication date: January 21, 2010Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp, Fortunata McConkey
-
Publication number: 20100008928Abstract: A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.Type: ApplicationFiled: October 4, 2007Publication date: January 14, 2010Applicant: TAKEDA PHAMARMACEUTICAL COMPANY LIMITEDInventors: Shuji Sato, Tsutomu Oshima, Tomofumi Kurokawa
-
Publication number: 20100003244Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.Type: ApplicationFiled: January 16, 2009Publication date: January 7, 2010Inventors: Gotz Munch, Meinrad Gawaz, Andreas Bultmann, Elisabeth Kremmer
-
Publication number: 20090324605Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: August 31, 2009Publication date: December 31, 2009Applicant: Medarex, Inc.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David Passmore
-
Publication number: 20090324599Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.Type: ApplicationFiled: November 13, 2008Publication date: December 31, 2009Applicant: AMGEN INC.Inventors: Arlen Thomason, Benxian Liu
-
Publication number: 20090328242Abstract: The present invention provides manufacturing processes for biological replication of undifferentiated plant and animal cells and tissue in a weightless condition, including those systems used in current stem cell research and development and use of undifferentiated parenchyma in plants. The present invention further provides methods for adapting plants and animals to survive outside their native environments. In particular, undifferentiated cells from plants or animals are replicated under weightless conditions in which cell replication or proliferation is accelerated and sustained. Under such conditions, the undifferentiated cells can be “forced” to express sets of genes useful for survival in particular environmental conditions. In this manner, cells surviving prolonged exposure to specific environmental conditions can be selected for and cultivated to produce an organism adapted to that particular environment in an accelerated manner.Type: ApplicationFiled: May 28, 2009Publication date: December 31, 2009Inventor: John W. Kennedy
-
Publication number: 20090317368Abstract: The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.Type: ApplicationFiled: April 9, 2009Publication date: December 24, 2009Inventor: Lieping CHEN
-
Patent number: 7635590Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: October 19, 2007Date of Patent: December 22, 2009Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Publication number: 20090311274Abstract: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.Type: ApplicationFiled: April 23, 2009Publication date: December 17, 2009Applicant: AGENSYS, INC.Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Mary Faris, Rene S. Hubert, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
-
Publication number: 20090311248Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.Type: ApplicationFiled: March 22, 2007Publication date: December 17, 2009Inventors: Erik Depla, Robert Purcell, Jens Bukh, Suzanne Emerson, Jean-Christophe Meunier
-
Publication number: 20090304579Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: May 15, 2009Publication date: December 10, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Publication number: 20090304588Abstract: As an alternative strategy to electronic pacemaker devices, we explored the feasibility of converting normally-quiescent ventricular myocytes into pacemakers by somatic cell fusion. The idea is to create chemically-induced fusion between myocytes and syngeneic fibroblasts engineered to express HCN1 pacemaker ion channels (HCN1 fibroblasts), in normally-quiescent myocardium. HCN1-expressing fibroblasts formed stable heterokaryons with myocytes, generating spontaneously-oscillating action potentials as well as ventricular pacemaker activity in vivo and provides a platform for an autologous, non-viral, adult somatic cell therapy. We also converted a depolarization-activated potassium-selective channel, Kv1.4, into a hyperpolarization-activated non-selective channel by site-directed mutagenesis (R447N, L448A, and R453I in S4 and G528S in the pore).Type: ApplicationFiled: October 16, 2006Publication date: December 10, 2009Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Eduardo Marban
-
Publication number: 20090285751Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: April 3, 2009Publication date: November 19, 2009Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Publication number: 20090285831Abstract: The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothielial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular the present invention relates to deimmunized such as humanized or human antibodies that bind to VEGF-B and inhibit the biological activity of VEGF-B. These antibodies have uses in the treatment or prevention of diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling. The present invention further contemplates a method of modulating diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies which bind to VEGF-B and block the biological activity of VEGF-B.Type: ApplicationFiled: March 13, 2009Publication date: November 19, 2009Applicant: ZENYTH OPERATIONS PTY LTDInventors: Andrew NASH, Giuseppe MACCARONE, Pierre David SCOTNEY
-
Publication number: 20090285824Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: December 20, 2005Publication date: November 19, 2009Applicant: AMGEN INC.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20090280082Abstract: The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune disorder is at least partially mediated by CD8+ T-cell proliferation.Type: ApplicationFiled: February 27, 2009Publication date: November 12, 2009Inventors: Nico GHILARDI, Frederic DeSauvage
-
Publication number: 20090280502Abstract: An antibody that reacts with 2-O-desulfated acharan sulfate, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The antibody that reacts with 2-O-desulfated acharan sulfate can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to 2-O-desulfated acharan sulfate.Type: ApplicationFiled: April 27, 2007Publication date: November 12, 2009Applicant: Seikagaku CorporationInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto, Yeong Shik Kim
-
Publication number: 20090280128Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: ApplicationFiled: December 20, 2006Publication date: November 12, 2009Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Publication number: 20090275126Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.Type: ApplicationFiled: July 17, 2009Publication date: November 5, 2009Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
-
Publication number: 20090275013Abstract: The invention is an assay for detection of Watermelon silver mottle virus (WSMoV)-serogroup tospoviruses using a monoclonal antibody and a method for preparing the monoclonal antibody. A hybridoma cell line that produces a monoclonal antibody against the NSs proteins of WSMoV-serogroup tospoviruses was produced. The hybridoma cell line produces a monoclonal antibody binding with peptide SEQ ID No. 19.Type: ApplicationFiled: April 24, 2007Publication date: November 5, 2009Inventors: Shyi-Dong Yeh, Tsung-Chi Chen
-
Publication number: 20090275048Abstract: An anti-acharan sulfate antibody, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The anti-acharan sulfate antibody can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to acharan sulfate.Type: ApplicationFiled: April 27, 2007Publication date: November 5, 2009Applicant: Seikagaku CorporationInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto, Yeong Shik Kim
-
Publication number: 20090258007Abstract: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.Type: ApplicationFiled: June 7, 2005Publication date: October 15, 2009Applicants: KYOWA HAKKO KOGYO CO., LTD., President National Cancer CenterInventors: Atsushi Ochiai, Norihiko Shiraishi, Yoko Kato, Toshio Ota, Susumu Sekine, Kenya Shitara, Akiko Furuya, So Ohta, Emi Hosaka, Yuka Sasaki
-
Patent number: 7601342Abstract: The invention is concerned with fusions of dendritic cells and antigen presenting cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy. The fusions according to the invention can also be used in methods for antigen discovery.Type: GrantFiled: January 24, 2007Date of Patent: October 13, 2009Assignee: Dana Farber Cancer InstituteInventors: Jianlin Gong, Donald Kufe
-
Publication number: 20090252747Abstract: A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.Type: ApplicationFiled: March 9, 2009Publication date: October 8, 2009Applicant: AGENSYS, INCInventors: Mary FARIS, Pia M. Challita-Eid, Aya Jakobovits, Arthur B. Raitano, Wangmao Ge
-
Publication number: 20090239216Abstract: A polynucleotide encoding a protein as defined in the following (a), (b) or (c): (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2; (b) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 with one or several amino acids substituted, deleted, inserted or added, and having a tannase activity; (c) a protein comprising an amino acid sequence showing 90% or more homology to the amino acid sequence as shown in SEQ ID NO: 2, and having a tannase activity.Type: ApplicationFiled: December 27, 2005Publication date: September 24, 2009Applicant: EISAI R & D MANAGEMENT CO., LTD.Inventors: Masanori Sasatsu, Norihisa Noguchi, Fuminori Moriyasu
-
Publication number: 20090220424Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: ApplicationFiled: January 15, 2009Publication date: September 3, 2009Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Weniu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Publication number: 20090221035Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XB1- or ATF6-mediated UPR pathway.Type: ApplicationFiled: April 6, 2009Publication date: September 3, 2009Applicant: WYETHInventors: Yijie Gao, Nicole M. Piche, Mei Geng, Stephen H. Herrmann, Xiaotian Zhong, Ronald Kriz, Zhijian Lu
-
Publication number: 20090215691Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: ApplicationFiled: December 15, 2008Publication date: August 27, 2009Applicants: Yale University, Biogen Idec MA Inc.Inventors: Daniel H.S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W.Y. Sah, Sylvia A. Rabacchi
-
Publication number: 20090214421Abstract: The present invention aims at developing a gene delivery system which has a high selectivity to a target cell and can introduce and express a gene with high efficiency, particularly developing such a system for use in a gene delivery therapy using a viral vector. The present invention provides a method for targeting a drug, which comprises the step of delivering a drug containing a therapeutic gene to a target site using an anti-PAP2a antibody.Type: ApplicationFiled: May 17, 2006Publication date: August 27, 2009Inventors: Hirofumi Hamada, Kiminori Nakamura, Kazunori Kato